Renaissance Technologies's ABT Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 558,066 shares of Abbott Laboratories (ABT) worth $69.92 M, representing 0.11% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 32 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in ABT, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2016, adding 2.32 M shares. Largest reduction occurred in Q2 2023, reducing 3.56 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2013 | +871,800 | New Buy | 871,800 | $38.33 |
| Q1 2014 | -871,800 | Sold Out | 0 | $0.00 |
| Q2 2014 | +1.5 M | New Buy | 1.5 M | $40.90 |
| Q3 2014 | -1.36 M | Reduce 90.36% | 144,983 | $41.59 |
| Q4 2014 | +714,217 | Add 492.62% | 859,200 | $45.02 |
| Q1 2015 | -446,900 | Reduce 52.01% | 412,300 | $46.33 |
| Q2 2015 | -412,300 | Sold Out | 0 | $0.00 |
| Q3 2015 | +1.35 M | New Buy | 1.35 M | $40.22 |
| Q4 2015 | -1.35 M | Sold Out | 0 | $0.00 |
| Q3 2016 | +657,300 | New Buy | 657,300 | $42.29 |
| Q4 2016 | +2.32 M | Add 353.43% | 2.98 M | $38.41 |
| Q1 2017 | +143,866 | Add 4.83% | 3.12 M | $44.41 |
| Q2 2017 | -2.06 M | Reduce 65.89% | 1.07 M | $48.61 |
| Q3 2017 | -1.07 M | Sold Out | 0 | $0.00 |
| Q2 2020 | +515,966 | New Buy | 515,966 | $91.43 |
| Q3 2020 | -515,966 | Sold Out | 0 | $0.00 |
| Q1 2021 | +364,866 | New Buy | 364,866 | $119.84 |
| Q2 2021 | -364,866 | Sold Out | 0 | $0.00 |
| Q3 2021 | +235,166 | New Buy | 235,166 | $118.13 |
| Q4 2021 | +1.34 M | Add 568.53% | 1.57 M | $140.74 |
| Q1 2022 | +1.57 M | Add 99.78% | 3.14 M | $118.36 |
| Q2 2022 | +1.08 M | Add 34.25% | 4.22 M | $108.65 |
| Q3 2022 | -1.69 M | Reduce 40.13% | 2.52 M | $96.76 |
| Q4 2022 | +240,308 | Add 9.52% | 2.76 M | $0.11 |
| Q1 2023 | +1.74 M | Add 63.03% | 4.51 M | $0.10 |
| Q2 2023 | -3.56 M | Reduce 79.03% | 945,069 | $0.11 |
| Q3 2023 | -857,603 | Reduce 90.75% | 87,466 | $96.85 |
| Q4 2023 | -87,466 | Sold Out | 0 | $0.00 |
| Q1 2024 | +836,766 | New Buy | 836,766 | $113.66 |
| Q2 2024 | +725,600 | Add 86.71% | 1.56 M | $103.91 |
| Q3 2024 | -1.56 M | Sold Out | 0 | $0.00 |
| Q4 2025 | +558,066 | New Buy | 558,066 | $125.29 |
Renaissance Technologies's Abbott Laboratories Investment FAQs
Renaissance Technologies first purchased Abbott Laboratories (ABT) in Q4 2013, acquiring 871,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Abbott Laboratories (ABT) for 32 quarters since Q4 2013.
Renaissance Technologies's largest addition to Abbott Laboratories (ABT) was in Q4 2016, adding 2,980,400 shares worth $114.48 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 558,066 shares of Abbott Laboratories (ABT), valued at approximately $69.92 M.
As of the Q4 2025 filing, Abbott Laboratories (ABT) represents approximately 0.11% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Abbott Laboratories (ABT) was 4,507,066 shares, as reported at the end of Q1 2023.